Repligen (RGEN) to Release Quarterly Earnings on Wednesday

Repligen (NASDAQ:RGEN - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $167.58 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the firm earned $0.23 EPS. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Trading Up 0.5 %

Shares of RGEN stock traded up $0.75 on Friday, hitting $146.92. 402,981 shares of the company's stock traded hands, compared to its average volume of 563,368. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a one year low of $113.50 and a one year high of $211.13. The company's fifty day simple moving average is $155.42 and its 200 day simple moving average is $149.08. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -397.07, a P/E/G ratio of 4.54 and a beta of 0.99.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. HC Wainwright dropped their price target on shares of Repligen from $240.00 to $180.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average target price of $186.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.